Portfolio company
Staten Biotechnology
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops monoclonal antibody therapies for patients with dyslipidaemia to reduce cardiovascular risk and lower triglyceride levels.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Shifa
This biopharmaceutical company develops oral small molecule drugs to treat cardiovascular disease and dyslipidemia for patients with high cholesterol.
NewAmsterdam Pharma
The company develops oral therapies to lower cholesterol in patients with cardiovascular disease whose symptoms are inadequately managed by standard statin treatments.
Marea Therapeutics
This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.
Omthera Pharmaceuticals
This biopharmaceutical company develops omega-3 fatty acid therapies to treat patients with dyslipidemia and high triglyceride levels.
MONCYTE Health
This company develops diagnostic tests to personalise cholesterol-lowering treatments for clinicians and pharmaceutical firms to prevent cardiovascular disease.
Brano Therapeutics
This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.
ScionxBio
This biotechnology company develops long-acting RNA medicines for pharmaceutical partners and patients with cardio-metabolic diseases.
Triveni Bio
This biotechnology company develops antibody-based therapies for patients with immunological and inflammatory disorders using a genetics-informed precision medicine approach.